Cargando…

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer

OBJECTIVE: The molecular mechanism of secondary resistance in Luminal breast cancer was studied to provide new ideas for the treatment of breast cancer. METHODS: The sensitivity of the downregulation of myeloid leukemia factor 1-interacting proteins (MLF1IP) to Tamoxifen (TAM) was tested by the Cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Minhua, Ding, Jinhua, Wen, Limu, Zhou, Yuxin, Wu, Weizhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990544/ https://www.ncbi.nlm.nih.gov/pubmed/33816619 http://dx.doi.org/10.1155/2021/6618519

Ejemplares similares

Role of lncRNA AGAP2-AS1 in Breast Cancer Cell Resistance to Apoptosis by the Regulation of MTA1 Promoter Activity
por: Wu, Minhua, et al.
Publicado: (2022)

Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Ding, Jinhua, et al.
Publicado: (2022)

An autophagy-related long non-coding RNA prognostic model and related immune research for female breast cancer
por: Chen, Jiafeng, et al.
Publicado: (2022)

“Elastic Stretch Cavity Building” System in Endoscopic Thyroidectomy of Giant Thyroid Tumors
por: Chen, Gaoxiang, et al.
Publicado: (2022)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Predictive Value of Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in Early Breast Cancer
por: Ding, Jinhua, et al.
Publicado: (2017)

Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
por: Abdel-Hafiz, Hany A.
Publicado: (2017)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers
por: Li, Qing-xia, et al.
Publicado: (2019)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Molecular heterogeneity of luminal breast cancer
por: Loi, S
Publicado: (2011)

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review
por: Fernandes, Leonor, et al.
Publicado: (2020)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

The molecular profile of luminal B breast cancer
por: Creighton, Chad J
Publicado: (2012)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer
por: Davey, Matthew G, et al.
Publicado: (2023)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

TET2 directs mammary luminal cell differentiation and endocrine response
por: Kim, Mi Ran, et al.
Publicado: (2020)

Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
por: Ding, Jinhua, et al.
Publicado: (2017)

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
por: Petrelli, Annalisa, et al.
Publicado: (2020)

How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?
por: Lapcik, Petr, et al.
Publicado: (2020)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer
por: Huang, Bowan, et al.
Publicado: (2023)

Identification of a Novel Luminal Molecular Subtype of Breast Cancer
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2014)

The molecular diversity of Luminal A breast tumors
por: Ciriello, Giovanni, et al.
Publicado: (2013)

Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer
por: Huang, Ting, et al.
Publicado: (2023)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
por: Cheng, Gary J., et al.
Publicado: (2022)

Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)

MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes - a feasibility study
por: Holli-Helenius, Kirsi, et al.
Publicado: (2017)

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer
por: Bai, Jing-Wen, et al.
Publicado: (2020)

NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers
por: Sun, Yunguang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hf7157p3ug4ir5b5j01isnjrgl